← Leaderboards
Gary A Piazza
Southern Research Institute
$25,461,125
Attributed
$28,634,353
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,348,068 · 15
By mechanism
U54$23,595,845 · 2
R01$15,816,755 · 6
R21$964,015 · 3
R43$524,879 · 2
R03$446,574 · 2
Top collaborators
- Robert C Reynolds6 shared
- Gang Zhou5 shared
- Joshua Canzoneri2 shared
- Yaguang Xi2 shared
- Bing Zhu2 shared
Most similar at Southern Research Institute
Same institution · by research overlap
- Robert C Reynolds$7,796,684
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellCell GrowthPropertyMalignant NeoplasmsTumorigenesisMouse ModelAntineoplastic AgentsIn VivoLeadTumorSeriesToxic EffectCancer ChemopreventionPharmaceutical PreparationsIn VitroIsoenzymesProstaglandin-Endoperoxide SynthaseChemopreventionGrowthCyclic GmpDrug KineticsNon-Steroidal Anti-Inflammatory AgentsApoptosisPhosphoric Diester Hydrolase
Grant awards (68)
Novel inhibitor for oncogenic RAS for lung cancer$381,222
R01 · FY2025 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$410,108
R01 · FY2024 · CA
Novel inhibitor for oncogenic RAS for lung cancer$360,373
R01 · FY2024 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$423,057
R01 · FY2023 · CA
Novel inhibitor for oncogenic RAS for lung cancer$395,336
R01 · FY2023 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$423,057
R01 · FY2022 · CA
Novel inhibitor for oncogenic RAS for lung cancer$390,583
R01 · FY2022 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$431,691
R01 · FY2021 · CA
Novel inhibitor for oncogenic RAS for lung cancer$394,586
R01 · FY2021 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$444,328
R01 · FY2020 · CA
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$267,424
R01 · FY2020 · CA · contact PI
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$167,347
R01 · FY2020 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$365,641
R01 · FY2019 · CA · contact PI
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$336,158
R01 · FY2019 · CA · contact PI
Enhancing the Immune System by Targeting the RAS Signaling Pathway in Cancer: Immunotherapeutic Potential of a Novel RAS Inhibitor for lung cancer treatment.$81,635
R01 · FY2019 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$376,950
R01 · FY2018 · CA · contact PI
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$346,556
R01 · FY2018 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$22,725
R01 · FY2018 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$385,363
R01 · FY2017 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$376,950
R01 · FY2017 · CA · contact PI
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$346,556
R01 · FY2017 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$151,500
R01 · FY2017 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$376,950
R01 · FY2016 · CA · contact PI
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention$346,556
R01 · FY2016 · CA · contact PI
Novel Ras inhibitor prodrug for colorectal cancer$300,000
R43 · FY2016 · CA
PDE Inhibition by Sulindac Sulfide Amide Derivatives for Lung Cancer Chemoprevention$164,756
R21 · FY2016 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$131,048
R01 · FY2016 · CA · contact PI
Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROS$128,775
R01 · FY2016 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$1
R01 · FY2016 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$445,790
R01 · FY2015 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$389,434
R01 · FY2015 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$252,538
R01 · FY2015 · CA · contact PI
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer$224,879
R43 · FY2015 · CA
PDE Inhibition by Sulindac Sulfide Amide Derivatives for Lung Cancer Chemoprevention$197,273
R21 · FY2015 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemoprevention$121,281
R01 · FY2015 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$566,975
R01 · FY2014 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$406,010
R01 · FY2014 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$424,008
R01 · FY2013 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$336,653
R01 · FY2013 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$160,041
R01 · FY2013 · CA · contact PI
MicroRNA, sulindac, and breast cancer chemoprevention$151,804
R21 · FY2013 · CA
Development of a novel sulindac amide for colorectal cancer chemoprevention$1
R01 · FY2013 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$1
R01 · FY2013 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$670,313
R01 · FY2012 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$438,973
R01 · FY2012 · CA · contact PI
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi$348,413
R01 · FY2012 · CA · contact PI
MicroRNA, sulindac, and breast cancer chemoprevention$193,793
R21 · FY2012 · CA
Development of a novel sulindac amide for colorectal cancer chemoprevention$62,504
R01 · FY2012 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$569,429
R01 · FY2011 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$414,101
R01 · FY2011 · CA · contact PI
Development of a novel sulindac amide for colorectal cancer chemoprevention$629,853
R01 · FY2010 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$1
R01 · FY2010 · CA · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$674,075
R01 · FY2009 · CA · contact PI
Southern Research Molecular Libraries Screening Center (SRMLSC)$1,185,983
U54 · FY2008 · HG · contact PI
Novel Sulindac Derivatives for Colon Cancer Chemoprevention$643,885
R01 · FY2008 · CA · contact PI
A novel sulindac derivative for colon cancer chemoprevention$110,049
R03 · FY2008 · CA · contact PI
SOUTHERN RESEARCH MOLECULAR LIBRARIES SCREENING CENTER (SRMLSC)(RMI)$4,768,215
U54 · FY2007 · HG · contact PI
An Integrated HTS Approach for the MLSCN Initiative(RMI)$4,504,510
U54 · FY2007 · HG · contact PI
Southern Research Molecular Libraries Screening Center (SRMLSC)$263,705
U54 · FY2007 · HG · contact PI
A Novel HTS Cell-Based Assay For Cyclic GMP$256,389
R21 · FY2007 · NS · contact PI
A novel sulindac derivative for colon cancer chemoprevention$108,011
R03 · FY2007 · CA · contact PI
Southern Research Molecular Libraries Screening Center (SRMLSC)$3,664,805
U54 · FY2006 · HG · contact PI
SOUTHERN RESEARCH MOLECULAR LIBRARIES SCREENING CENTER(R$3,488,523
U54 · FY2006 · HG · contact PI
South Research Molecular Libraries Screening Center(RMI)$44,202
U54 · FY2006 · HG · contact PI
South Research Molecular Libraries Screening Center(RMI)$3,050,510
U54 · FY2005 · HG
SOUTHERN RESEARCH MOLECULAR LIBRARIES SCREENING CENTER(R$2,625,392
U54 · FY2005 · HG
cGMP Phosphodiesterase, a Novel Chemoprevention Target$114,257
R03 · FY2005 · CA
cGMP Phosphodiesterase, a Novel Chemoprevention Target$114,257
R03 · FY2004 · CA